Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Icotinib versus chemotherapie als adjuvante behandeling stadium II-IIIA EGFR-gemuteerd NSCLC
jan 2022 | Longoncologie